Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | STAT6 | P42226 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CFD | P00746 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980682 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL4976717 | 0.91 | KDM4E (0.52) | ALDH1A1KDM4EKMT2AHSP90AB1 | |
| SCHEMBL4976734 | 0.91 | KDM4E (0.52) | ALDH1A1KDM4EKMT2AHSP90AB1 | |
| SCHEMBL4976818 | 0.90 | HSP90AB1 (0.42) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL4976823 | 0.90 | HSP90AB1 (0.42) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL4979716 | 0.88 | HSP90AB1 (0.42) | MEN1KMT2AATMMAPTHSP90AB1 | |
| SCHEMBL4979726 | 0.88 | HSP90AB1 (0.42) | MEN1KMT2AATMMAPTHSP90AB1 | |
| SCHEMBL4978895 | 0.87 | HSP90AB1 (0.42) | ALDH1A1KDM4EHPGDKMT2AMAPT | |
| SCHEMBL4978885 | 0.87 | HSP90AB1 (0.42) | ALDH1A1KDM4EHPGDKMT2AMAPT | |
| SCHEMBL4981982 | 0.87 | ALDH1A1 (0.46) | ALDH1A1MAPTTP53HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | ALDH1A1 1142/4885KDM4E 1865/4885HPGD 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.